ASX Value Debate: Downer EDI DOW Infrastructure Cyclical vs Cochlear COH Premium Healthcare in 2026

The Quick Take

• Downer EDI (ASX: DOW) and Cochlear (ASX: COH) are two contrasting ASX-listed stocks — an infrastructure services company versus a medical devices manufacturer — being compared for relative value in 2026.
• Cochlear trades at a significant premium valuation multiple reflecting its dominant global position in implantable hearing solutions and a defensive, recurring upgrade revenue model.
• Downer EDI offers a lower valuation entry point as an infrastructure and facilities management services provider, with earnings tied more directly to government contract cycles and construction activity.

Rask Media's analysis of Downer EDI (ASX: DOW) and Cochlear (ASX: COH) frames a classic Australian equities valuation debate: growth premium versus cyclical value. Cochlear is a globally dominant medical device manufacturer producing implantable hearing solutions with a proven recurring revenue model as patients upgrade processors over time; the stock has historically commanded a high earnings multiple reflecting its consistent growth, pricing power, and international revenue diversification across the US, Europe, and Asia-Pacific. Downer EDI, in contrast, operates as a large-scale infrastructure services and facilities management company with revenues driven by Australian government contracts and construction activity cycles.

The relative value comparison matters for ASX-focused investors because both companies represent long-duration investment theses with very different risk profiles: Cochlear's premium multiple embeds an expectation of sustained above-market earnings growth, meaning any volume miss or reimbursement rate pressure in key markets creates disproportionate de-rating risk. Downer EDI has spent recent years divesting non-core businesses to focus on government-linked infrastructure services, a simplification that reduces earnings volatility but caps the upside multiple relative to pure growth plays. For portfolio construction, the DOW versus COH comparison essentially maps a value-versus-quality trade-off within the ASX mid-large cap space.

The forward signals to watch are Cochlear's next implant volume and upgrade cycle data for its Americas and EMEA regions — a continued strong replacement cycle supports the premium valuation — and Downer EDI's contract renewal rate and margin trajectory on its infrastructure services portfolio as inflation in labour and equipment costs flows through to margins. The macro variable is Australia's fiscal expenditure profile: any acceleration in government infrastructure investment increases the addressable contract pipeline for Downer while simultaneously diverting capital away from discretionary healthcare spend that could flow to hearing-upgrade procedures in Cochlear's markets.

Synthesized from 1 source.